Apr 26, 2022
This study evaluates the potential impact of Mavacamten in severely symptomatic patients with obstructive hypertrophic cardiomyopathy to reduce the need for septal reduction therapy. It studies a first of its kind new cardiac myosin inhibitor.
In this interview, Milind Desai MD, MBA and Matthew Martinez MD, FACC, with...
Apr 19, 2022
Clinicians often recommend dietary sodium reduction for almost all their patients with HF. Whether or not this practice should continue remains an uncertain question in almost every clinic visit. We spend a fair amount of time counselling patients on this, and patients want to know if they need to undertake a full...
Apr 12, 2022
Heart failure patients experience exercise intolerance and functional limitation every day. While the targeting of functional capacity is an important unmet need, this study found that the change in peak oxygen uptake did not differ between patients taking omecamtiv mecarbil and placebo.
How do current...
Apr 5, 2022
Heart failure patients are generally multi-morbid and at risk for hyperkalemia, which makes treatment with life-saving therapies like RAASi difficult and leads to compromised medical treatment and in turn poor outcomes. This trials showed that with the use of patiromer, one can simultaneously lower the risk of...